Tislelizumab with Chemotherapy for Limited-Spread Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of tislelizumab (a type of immunotherapy) with chemotherapy, with or without radiation, for people with small cell lung cancer that has spread to only a few places in the body. The goal is to see if this combination helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called small cell lung cancer that has spread to a limited number of other areas in your body (no more than 3 different organs and no more than 5 spots total).
- You are in generally good health, able to take care of yourself and do light activities (ECOG score of 0 or 1).
- You have not had any previous treatment for this cancer, like chemotherapy or radiation.
- You are at least 18 years old and weigh more than 40 kilograms (about 88 pounds).
- You have not had an autoimmune disease that requires treatment with steroids or other immune-suppressing medicines.
- Your heart, liver, kidneys, and bone marrow are working well enough according to recent tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests a combination of an immunotherapy drug (tislelizumab), chemotherapy, and then radiation to the chest for people with extensive-stage small cell lung cancer who haven't had prior treatment. The goal is to see if this approach helps control the cancer longer.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether taking tislelizumab plus nintedanib after initial radiation and chemotherapy can help keep limited-stage small cell lung cancer from coming back. It is for people who have finished induction treatment and are in good overall health.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.